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Celiac disease remains the dominant 
small intestinal pathology. Can celiac disease 
also be diagnosed in adults without histology 
as recommended in the ‘biopsy-sparing’ gu-
idelines for children? A recent study revealed 
that high anti-tissue transglutaminase and an-
ti-endomisial antibodies in HLA-DQ2/DQ8 
symptomatic patients correlated with villo-
us atrophy in over 90%, and that increasing 
levels of anti-tissue transglutaminase were 
paralleled by increasing severity of duode-
nal damage. Despite such findings, duode-
nal histology (1–2 biopsies in the bulb and 4 
biopsies from the second duodenum) is still 
the gold standard in adults because: anti-tis-
sue transglutaminase antibodies can be false 
positive, biopsies can rule out coincidental 
pathologies, comparison of initial biopsies 
with subsequent biopsies may be useful as up 
to 30% of adult celiacs may have persistent 
atrophy despite gluten-free diet, and biopsies 
are necessary for the diagnosis of complica-
tions such as refractory celiac disease and 
enteropathy-associated T cell lymphoma.
Non-celiac gluten (wheat) sensitivity 
is a condition in which ingestion of gluten 
induces gastrointestinal and extra-intestinal 
symptoms, and complaints occur in the ab-
sence of celiac disease or wheat allergy. The 
clinical picture may overlap with irritable 
bowel syndrome. So far there are no reliab-
le biomarkers to identify such individuals. 
The pathogenesis is not completely under-
stood and the culprit molecule is unknown 
(gluten?, fructans in FODMAPS?, amylase 
trypsin inhibitors?). In last year’s highlights 
(Gastro Update Europe 2017) it was mentio-
ned that of such gluten-free diet responders, 
only 14% relapsed upon gluten challenge, 
raising doubt that gluten is the culprit in the 
majority of such gluten-sensitive patients. 
Fructans, rather than gluten, was shown to 
induce symptoms in such patients with self-
-reported non-celiac gluten sensitivity. Cur-
rently consumption of gluten-free food pro-
ducts is highly promoted in the community 
without consideration of potentially negati-
ve long-term consequences. Indeed, a recent 
prospective study indicated that high gluten 
consumption was associated with a decrea-
sed risk of coronary heart disease. Avoidance 
of gluten may result in reduced consumption 
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of beneficial whole grains, which may affect 
cardiovascular risk. The promotion of glu-
ten-free diets among people without celiac 
disease should not be encouraged.
A severe sprue-like enteropathy may 
occasionally occur in patients treated with 
Olmesartan (an angiotensin receptor bloc-
ker), rarely with telmisartan or valsartan. 
Results of epidemiological studies however 
remain conflicting. The incidence appeared 
to be higher in older patients, those treated 
for longer periods and those receiving high 
cumulative doses. Although the absolute rate 
is low, Olmesartan should always be consi-
dered as a potential cause when evaluating 
patients with enteropathy.
Management of small bowel angiod-
ysplasia remains problematic. Rebleeding 
occurs in 20–40% despite (optimal ?) en-
doscopic therapy. A prior meta-analysis 
suggested that somatostatin analogs could 
reduce rebleeding and transfusion require-
ments; this was confirmed in a recent place-
bo-controlled trial which evaluated the effica-
cy and safety of pasireotide-LAR in patients 
with refractory bleeding. A decrease of at 
least 30% of pRBC transfusion was obtained 
in 83% with pasireotide-LAR compared to 
25% with placebo. New is the emerging role 
of thalidomide in the treatment of patients 
with challenging gastrointestinal bleeding. 
The current therapeutic algorithm is illustrat-
ed below [Becq et al., Gastrointest Endosc 
2017; 86(5): 792–806] (Fig. 1).
A European consensus group recom-
mends fecal microbiota transplantation 
(FMT) for both mild and severe recurrent 
clostridium difficile infection, to be carried 
out also in clinical practice. FMT can be done 
in different ways. A recent controlled trial 
compared the effect of oral capsule FMT ver-
sus colonoscopy-delivered FMT. Prevention 
of recurrent infection after a single treatment 
was obtained in 96%, both for the capsule 
group and the colonoscopy group. A signi-
ficantly greater proportion of participants 
receiving capsules rated their experience as 
‘not at all unpleasant’ (66 vs 44%).
Is fecal microbiota transplantation 
helpful in ulcerative colitis? Two prior trials, 
using one donor for every patient, gave rather 
conflicting outcomes. Recently, a placebo-
-controlled trial with multi-donor intensive 
fecal microbiota transplantation was carried 
out in active ulcerative colitis. Steroid-free 
clinical remission and endoscopic remission 
or response was seen in 27% after FMT, vs 
8% after placebo. Combining all availab-
le studies in ulcerative colitis would indi-
cate a 20% increase in combined clinical 
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Figure 1. Therapeutic algorithm [Becq et al., Gastrointest Endosc2017; 86(5): 792–806]
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remission and endoscopic remission/respon-
se. To identify those colitis patients that will 
respond to FMT and the optimal FMT tech-
nology will require substantial further rese-
arch before such therapy can be used in cli-
nical practice, but the results so far obtained 
are intriguing and challenging.
Is fecal microbiota transplantation 
helpful in irritable bowel syndrome? A pla-
cebo controlled trial was carried out in pa-
tients with diarrhea, or with diarrhea and con-
stipation, scored as moderate to severe. The 
fecal transplant was administered by colono-
scopy to the cecum. A reduction in symptoms 
after 3 months was observed in 65% after 
FMT compared to 43% after placebo. Here 
again, many more studies will be necessary 
focusing on proper patient selection, proper 
FMT technology and proper evaluation of 
the long-term outcome before FMT is ready 
for prime time therapy.
The 6th Gastro Update Europe is June 14 
– 15, 2019 in Budapest (www.gastro-update-
-europe.eu)
Peter Layer
Germany 
Novel developments in pancreatic  
disorders — presentation at Gastro  
Update Europe 2018, Prague
Review written by Guido NJ Tytgat Prof Em Division  
of Gastroenterology Hepatology, Amsterdam UMC-location  
Academic Medical Center, Meibergdreef,  
105 AZ Amsterdam, Netherlands  
Massive hypertriglyceridemia is a well 
established cause of acute pancreatitis. Less 
clear is the role of lower triglyceride levels. 
In an impressive prospective study, sequen-
tial triglyceride levels were determined in 
116,550 individuals during a mean follow-up 
of 6.7 years. As shown below, pancreati-
tis risk increased by 20% when triglyceride 
levels rose by 100 mg/dl; for comparison, 
the rising risk of myocardial infarction is 
also shown [JAMA Intern Med 2016; 176: 
1834–1842] (Fig. 2).
The pancreatitis risk is dose-dependent 
with a postprandial threshold of > 200–300 
mg/dl. The true mechanisms by which high 
triglyceride levels induce pancreatitis needs 
further study. 
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Figure 2. Pedersen et al., JAMA Intern Med 2016; 176: 
1834–1842
Also, the visceral adipose tissue mass 
quantified by CT as area of fatty tissue in cm2 
on day 1 of admission has been shown to be 
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an important predictor of pancreatitis sever-
ity, and the risk of necrosis and multi-organ 
failure. Visceral adipose tissue is metaboli-
cally highly active. By which mechanism it 
raises acute pancreatitis severity needs fur-
ther exploration.
Volume substitution is essential in the 
management of acute pancreatitis. In a re-
cent prospective study, 60 patients with acute 
pancreatitis, ’aggressive’ hydration with 
Ringer’s lactate solution (20 ml/kg bolus, 
followed by 3 ml/kg/h continuous infusion) 
was compared with ‘standard’ hydration (1.5 
ml/kg/h continuous infusion) with protocol 
adaptation every 12 h, depending on lab and 
clinical data. As can be seen, early, vigorous 
and subsequent adequate volume hydration 
improves the course of pancreatitis. This 
therapy, which consisted initially in 1–2 L, 
followed by about 3 L /12 h was well tol-
erated [A J Gastroent 2017; 112: 797–803] 
(Fig. 3). One may question whether the vol-
ume of 1.5 L in the first 12 h in the standard 
group was adequate.
The therapy of acute necrotising pan-
creatitis has changed from early emergency 
open surgery and necrosectomy, to late elec-
tive and strictly selective minimally invasive 
approaches, alongwith endoscopic interven-
tions. The success of such paradigm shift was 
shown in a large retrospective multicenter 
study involving 1,980 patients with acute ne-
crotising pancreatitis. Mortality was 2 fold 
higher when open surgery was compared to 
minimally invasive surgery, and mortality 
was 5 fold higher when open surgery was 
compared to endotherapy. As shown below, 
the overall reduction in relative mortality 
illustrates definite progress in the manage-
ment of this dreadful disease [Gut 2018; 67: 
697–706] (Fig. 4).
Thus, the initial therapeutic approach 
should focus on early adequate volume 
substitution and conservative non-surgical 
management even with infected necrosis to 
avoid massive intervention trauma in the 
early phase. During the further course of 
the disease with/without infected necrosis, 
intervention should be selective and rather 
delayed, minimizing iatrogenic trauma as 
far as possible and exploring first the en-
dotherapeutic possibilities. Note that 50–
70% of patients may achieve full recovery 
without any intervention, even with infect-
ed necrosis.
Early cholecystectomy for acute biliary 
pancreatitis is associated with a lower risk 
of relapsing acute pancreatitis (particular-
ly in the presence of small gallstones) and 
is the current standard, cost effective strate-
gy. A recent American study involving over 
17,000 patients showed a reduction of acute 
pancreatitis relapse from 13% to 3% with 
respectively delayed/absent cholecystomy 
(22% of patients) and early cholecystecto-
my (78% of patients). Thus cholecystecto-
my should be performed within 4 weeks af-
ter biliary acute pancreatitis, and whenever 
possible even during the same hospital stay. 
It provides effective protection against im-
minent relapse and does not interfere with 
recovery from acute pancreatitis.
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Prevention of post-ERCP is of major 
clinical importance and is often carried out 
with rectal administration of NSAIDs 30 min 
prior to ERCP. In a recent study 372 patients 
were evaluated, comparing diclofenac 100 
mg, indomethacin 100 mg, and naproxen 500 
mg. The overall pancreatitis rate was 8.6% 
with the lowest rate after diclofenac or indo-
methacine and the highest rate after naprox-
en, which might therefore be ineffective. 
Vigorous hydration using lactated Ringer’s 
solution may also prevent post-ERCP pancre-
atitis. In a large prospective study involving 
510 patients, standard hydration (infusion 
of 1.5 ml/kg/h during ERCP and for 8 h af-
ter ERCP) was compared to vigorous hydra-
tion (bolus of 10 ml/kg pre- and post ERCP 
plus infusion of 3 ml/kg/h during and for 8 
h after ERCP). Overall pancreatitis dropped 
from 9.8 to 4.3% and hyperamylasemia from 
16.1 to 6.7% when standard was compared 
to vigorous hydration.
In a randomized controlled trial involv-
ing 192 patients at high risk for post ERCP 
pancreatitis, vigorous lactated Ringer’s solu-
tion was combined with or without indometh-
acine and resulted in a drop of pancreatitis 
rate from 19% to 6% respectively, indicating 
that combination should be considered espe-
cially for risky situations.
The diagnosis of autoimmune pancre-
atitis remains difficult in many patients; 
the clinical presentation is highly variable, 
IgG4 levels may not be elevated, especial-
ly in Europe, typical aberrations in imag-
ing studies are seen in less than 30% and 
the contribution of EUS-guided histology/
cytology is uncertain. A recent study in-
volving 50 patients with suspected autoim-
mune pancreatitis revealed that EUS-FNA 
with a 22 gauge needle was diagnostically 
not effective in most patients, contributing 
to diagnostic accuracy in only 16%. Con-
vincing clear-cut response to corticosteroids 
remains the most reliable criterion. A recent 
study evaluated the relapse prevention in 49 
patients after induction of remission with 
prednisolone 0.6 mg/kg/d for 12 w followed 
by tapering. In the control ‘cessation’ group, 
steroids were terminated after 6 m and in 
the ‘maintenance’ group prednisone 5–7.5 
mg/d was continued for 3 y. In the control 
cessation group, relapse occurred in 58% 
compared to 23% in the predisone mainte-
nance group. Maintenance steroid therapy 
with the lowest effective dose may therefore 
be appropriate.
The debate continues with respect to the 
proper strategy for patients with intraductal 
papillary mucinous neoplasia (IPMN). A re-
cent meta-analysis was performed related to 
the course of non-resected IPMN shown be-
low [Clin Gastro Hepatol 2017; 15: 1509–
1520] (Fig. 5).
Several strategies and guidelines for 
branch-duct IPMN have been published. Sur-
veillance with MRI and/or EUS is usually 
advised for operable patients with no worri-
some features or high risk factors; surveil-
lance is recommended after 6–12 m during 
the first y and after 6–24 m (~yearly) from 
the second y on for over 5 y. Surveillance 
should be carried out at shorter intervals for 
cysts > 2–3 cm or if relevant changes occur 
(cyst growth > 3 mm; changes in cyst cytolo-
gy, CEA, serum CA19-9, new diabetes). Sur-
gery is to be considered if worrisome features 
or high risk factors develop. Note that risk 
never ceases, even after surgery, and there-
fore surveillance should be continued also 
post-surgery. Keep in mind that ultimately 
the fitness of the patient turns out to be over-
all more important than worrisome features 
and risk factors.
The 6th Gastro Update Europe is June 
14–15, 2019 in Budapest (www.gastro-up-
date-europe.eu)
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Figure 5. Choi et al., Clin Gastroenterol Hepatol 2017; 15: 
1509–1520
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Inappropriate use of PPIs continues at 
a high rate which is disappointing and fran-
kly unacceptable! This was again stressed 
in a recent systemic review, showing that 
43% initiation of long-term PPI therapy in 
hospital was inappropriate. What a waste of 
resources.
The list of PPI-related adverse effects, 
shown in the highlights of the 2017 update 
(Gastro Update Europe 2017), is essentially 
unchanged also with respect to variability in 
interpretation of their clinical relevance. No-
vel are population-based studies from Hong 
Kong and Sweden, indicating that the risk 
of gastric cancer during prolonged PPI the-
rapy at least doubles compared to controls; 
also after H. Pylori eradication for those that 
were infected [Gut 2018; 67: 28; BMJ Open 
2017; 7: e017739]. Speculative mechanisms 
for these alarming (?) findings might inclu-
de PPI-induced dysbiosis with potential ni-
trosamine formation in the presence of on-
going hypergastrinemia. Long-term PPI use 
was also shown to increase the risk of esop-
hageal adenocarcinoma, also in non-GERD 
patients [Cancer Epidemiol 2018; 53: 172]. 
Despite the shortcomings and criticisms vo-
iced in the literature, such novel information 
is quite shocking and should remind us all 
of the old adage: drugs should be given in 
the lowest effective dose and for the shortest 
appropriate time. Finding the right balance 
Gastroesophageal reflux disease (GERD, 
NERD) remains the dominant esophageal 
pathology. In selected patients, especially 
those with persistent symptoms, ambulatory 
pH-impedance monitoring and high resolu-
tion manometry may be of value in determi-
ning the reflux burden and the reflux-symp-
tom association, but this usually requires re-
ferral to an expert center. Acid suppression 
remains the mainstay of therapy both for 
GERD and NERD, but anti-reflux surgery 
(although less frequently performed) still has 
a definite role in case of persistent symptoms, 
also for NERD, especially if the esophago-
gastric junction is compromised. Once daily 
PPI, preferably before breakfast, remains the 
standard occasionally upregulated to twice 
daily. Important novel competitors for PPIs 
are the pCABs (potassium competitive acid 
blockers), already available for clinical use in 
Japan and Korea. pCABs such as Vonoprazan 
are not acid-sensitive, do not require gastric 
coating, and provide rapid, strong and long 
lasting acid suppression from day ,1 with so 
far superior results in GERD, H. Pylori era-
dication therapy, prevention of bleeding, etc. 
compared to PPIs without significant side ef-
fects. Reflux symptoms can also be impro-
ved, not only by co-administration of algi-
nates, but also with ESOXX, a novel hyalu-
ronic acid-chondroitin sulphate bioadhesive 
mucosal protective.
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between benefit and risk will remain a deli-
cate medical enterprise.
Why the incidence of eosinophilic es-
ophagitis (EoE) continues to rise as shown 
below, apparently quite in parallel with the 
rising PPI consumption, remains enigmatic 
despite many hypotheses (Fig. 6).
Recently, Spechler [Cur Gastroent Rep 
2018; 20: 26] hypothesized that increasingly 
consumed PPIs (especially in children) pre-
vent pepsin proteolysis of potentially aller-
genic proteins because of gastric pH rise > 
4.5 (instead of rapid acid-peptic hydrolysis 
to small non-allergenic peptides). Moreover, 
PPIs facilitate gastric absorption of peptide 
fragments because of enhanced PPI-induced 
permeability, ultimately leading to systemic 
exposure and sensitization. Further oral in-
take of those allergens after sensitization 
exposes the esophageal mucosa which may 
induce a Th2-geared inflammatory eosinop-
hilic response.
Early diagnosis of EoE remains of 
upmost importance as progression from an 
inflammatory to a fibrostenotic phenotype oc-
curs quite rapidly if left untreated. With each 
additional year of undiagnosed EoE, the risk 
of stricturing has been shown to increase by 
9%. Suspicion for EoE, prompting endosco-
py and histology, should be raised when a pa-
tient presents with: a history of atopy, history 
of food impaction, PPI refractory symptoms 
and either peripheral eosinophilia or elevated 
IgE levels. For diagnosis at least 6 biopsies 
should be obtained from different locations, 
focusing on areas of mucosal abnormality. 
Recent studies confirmed that none of the 
standard allergy tests can accurately predict 
the actual specific food triggers. The com-
mon triggers remain wheat, milk and egg, 
alone or in combination. Investigations with 
food exclusion/rechallenge with repetitive 
histological assessment remain an effective 
strategy but is difficult and hardly carried 
out in clinical practice. The same can be 
said for elemental diet (e.g. Neocate, Nu-
tricia, Netherlands) which has been clearly 
shown to decrease inflammation and to im-
prove symptoms, but such therapy is impra-
ctical in adults if prescribed long-term. The 
main therapy after a trial with PPI is based 
on topical corticosteroids. Budesonide oral 
suspension has been shown to be effective 
in improving symptoms and endoscopic se-
verity scores. Also novel and quite effective 
is budesonide orodispensible 1mg tablets, 
given BID (already available in Germany). 
Topical steroids may increase the risk of 
candidiasis. Also novel is an anti-IL-13 mo-
noclonal antibody shown to be effective in 
steroid refractory cases.
European guidelines on EoE manage-
ment have recently been published (Fig. 7).
It was again confirmed that H. Pylo-
ri infection doubles the risk of peptic ulcer 
bleeding in aspirin/NSAID users with even 
further risk increase in users of combined 
anti-platelet therapy. Bleeding risk did not 
increase in patients on anticoagulants, SSRIs 
or corticosteroids. Eradication therapy is 
therefore indicated particularly in long-term 
users of mucosa-damaging drugs. Although 
not-covered at the meeting, it may be wort-
hwhile to mention the additional protective 
effect of PPIs in long-term aspirin/NSAID 
users. However, insufficiently recognized 
by clinicians is that PPIs only protect the 
gastroduodenum but may aggravate dama-
ge further down in the intestinal tract; this 
is especially so for entero-hepatic circula-
ting NSAIDs.
It was also again confirmed in a mega 
Chinese controlled trial that after endoscopic 
resection of early gastric cancer patients had 
lower rates of metachronous gastric cancer, 
shown below together with more improve-
ment of corpus mucosal atrophy if H. Pylori 
was eradicated (Fig. 8).
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However, H. Pylori eradication was not 
protective in all patients. H. Pylori eradica-
tion may fail to prevent metachronous ga-
stric cancer in those with advanced atrophy, 
intestinal metaplasia and a(hypo)chlorhydria, 
indicating a ‘point of no return’. As it is not 
really possible to predict where and when the 
‘point of no return’ is reached, patients with 
precancerous lesions may still benefit from 
H. Pylori eradication which may slow down 
the progression to more advanced disease as 
shown in a recent study. Particularly patients 
with so-called ‘incomplete-type of intestinal 
metaplasia’ are at high cancer risk with on-
going H. Pylori infection.
Useful prediction of gastric cancer risk 
has been shown to be possible by measuring 
pepsinogen 1 and anti-H. Pylori whole cell 
or CagA antibody levels. If the latter are pos-
itive, gastroscopy should be performed. In-
creasingly discussed is the question whether 
gastroscopy should be combined with screen-
ing colonoscopy during the same examina-
tion. An additional reason for combining gas-
troscopy with colonoscopy is the recognition 
that the risk of (advanced) colonic adenoma 
appears to be increased in H. Pylori infected 
individuals, particularly with gastric atrophy 
(hypergastrinemia?). This is further support-
ed by a recent Korean study, finding a 1.34 
fold higher prevalence of advanced colorec-
tal cancer in H. Pylori seropositive patients.
Figure 7. Lucendo et al., United European Gastroenterol J. 2017; 5(3): 335–358. *In patients with persistent symptoms 
under anti-inflammatory therapy, endoscopic dilation should be considered; ** Refer the patient to an EoE center
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Clarithromycin resistance has been ris-
ing in many countries over the past decades, 
reaching 30% in Japan and Italy, 40% in 
Turkey and 50% in China. Other antibiot-
ics (metronidazole, levofloxacine) showed 
a similar, though usually lower trend. Re-in-
terest in bismuth quadruple therapy is rising. 
In a recent large scale Chinese study H. Py-
lori eradication rates with 10d bismuth quad-
ruple therapy (O-BMT), 10d concomitant 
therapy and 14d standard triple therapy were 
respectively 90%, 86%, and 84%.
Ideally, antimicrobials prone to resist-
ance should be avoided for mass application 
to lower additional resistance selection pres-
sure on pathogens other than H. Pylori. Bis-
muth, tetracycline and metronidazole are of 
lesser importance in managing other bacteri-
al infections. Moreover, resistance does not 
occur or is of lesser critical importance for 
metronidazole. All this favors the selection 
of bismuth quadruple therapy as a first line 
therapy, as shown in the recent Maastricht 
V/Florence consensus report [Gut 2018; 66: 
6–30] (Fig. 9).
The 6th Gastro Update Europe is June 
14 – 15, 2019 in Budapest (www.gastro-up-
date-europe.eu)
Figure 9. Malfertheiner et al., Gut 2018; 66: 6–30
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follow-up study involving 2,697 Barrett pa-
tients. The primary outcome parameter was 
the development of high-grade dysplasia/
early adenocarcinoma during a median 5.9 y 
follow-up period. In low risk Group (0–10 po-
ints) progression risk was 0.13%/y. In the in-
termediate risk Group (11–20 points) progres-
sion risk was 0.73%/y. In the high risk Group 
(> 20 points) progression risk was 2.1%/y.
Treatment op post-operative esophage-
al leakage can be: conservative (watch and 
wait, nil per os, tube feeding); per-endosco-
pic (OTS-clip, stent, endovac sponge thera-
py); surgical (anastomosis redo). A recent 
prospective evaluation of endoscopic va-
cuum therapy was carried out in 52 patients 
of which 75% had post-surgical leakage. 
First line therapy was endoscopic vacuum 
therapy with intraluminal or intracavitary 
sponge placement with 2 changes/w and with 
100–125 mm Hg negative pressure. Between 
1–25 (~6) sponges were used. The defect he-
aled in 94% of those only treated with spon-
ges. Minor (dislocation, bleeding) and ma-
jor (fatal bleeding) complications occured 
in respectively 31% and 4% of the patients. 
In-hospital mortality (bleeding, multi-organ 
failure, pneumonia) was 10%. Comparative 
studies are needed to find out which treat-
ment modality is preferable for each anato-
mical presentation.
Surveillance recommendations, accord-
ing to ESGE guidelines vary according to the 
length of the Barrett segment. Surveillance 
varies from: none for < 10 mm; every 5 y for 
< 3 cm; every 3 y for < 10 cm; and surveil-
lance in a Barrett expert center if > 10 cm. 
Difference in expertise between a commu-
nity hospital and an expert center was ana-
lysed in a retrospective multi-centric study 
involving 198 patients with high-grade dys-
plasia/adenocarcinoma. Detection of a visi-
ble lesion occurred respectively in 60% vs 
~90%. In 40% neoplasia was only detected 
on non-targeted biopsies in community hos-
pitals but was endoscopically detected in 
75% by experts. 
A new classification using acetic acid 
chromoendoscopy (PREDICT) has been pre-
sented shown below [Gut 2017-314512 /Sep 
28 2017] (Fig. 10).
Acetic acid staining using this classi-
fication is easy to learn and can improve 
diagnostic performance in detecting Barrett 
neoplasia.
A model was developed to determine the 
risk of malignant progression of Barrett esop-
hagus.The scoring system involved: Barrett 
length (1 point for each cm); male gender (9 
points); smoking (5 points); low-grade dys-
plasia at baseline (11 points). The model was 
evaluated retrospectively in a longitudinal 
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Standard criteria for endoscopic resec-
tion of early gastric cancer are: mucosal, 
G1-2, L0, V0, up to 20 mm. Novel expanded 
criteria are: submucosal sm1/<500microm 
or G3, or > 20 mm or < 30 mm in ulcerated 
lesions. Gradually ESD data from Europe 
is also becoming available as illustrated by 
a recent study involving 179 patients with 
191 ESDs. ESD was incomplete because of 
‘non-lifting’ in 5%. En-bloc resection and 
RO-resection were respectively 92% and 
76%. Major complications (bleeding, perfo-
ration) occurred in 8% and procedure-related 
mortality was 1%. According to standard and 
expanded criteria, local recurrence was seen 
in 0 vs 5%, metachronous lesions in 15 vs 
7%, need for surgery in 0 vs 7% and total de-
ath/cancer death in (13%/0%) vs (18%/0%). 
Beyond doubt ESD for early gastric cancer 
will continue to expand in Europe in paral-
lel with more refined methodology for lesion 
delineation etc, but for the time being such 
therapy will be restricted to dedicated expert 
centers because the patient volume is so far 
rather limited.
The risk of lymphnode metastasis in ear-
ly gastric cancer is rather low, as again shown 
by a meta-analysis of 12 studies involving 
9,798 gastrectomised patients. Lymphnode 
metastasis for standard vs expanded criteria 
lesions were respectively 0.2% and 0.7%, for 
differentiated mucosal cancer < 3 cm with 
ulceration 0.57%, for differentiated mucosal 
cancer without ulceration 0.27% m, for un-
differentiated mucosal cancer < 2 cm 2.6% 
and for differentiated submucosal cancer < 3 
cm 2.5%. It is clear from such data that grade 
of differentiation and presence of ulceration 
are important prognostic features.
The role of H. Pylori eradication (amo-
xicillin-clarithromycin-rabeprazole) after 
gastric ESD for early gastric cancer or high-
-grade dysplasia was evaluated in a large 
prospective placebo-controlled trial invol-
ving 470 patients, followed-up for a median 
of 5.9y. In the eradication group (successful 
in 80%) and the placebo group, metachrono-
us cancer occurred in respectively 7.2% vs 
13.4% and improvement of gastric mucosal 
atrophy in 48.4% vs 15%. Thus the risk for 
metachronous gastric cancer after successful 
eradication dropped to an HR of o.32. After 
ESD, but also after partial gastrectomy for 
more advanced cancer, H. Pylori eradication 
should be carried out.
The 6th Gastro Update Europe is June 
14 – 15, 2019 in Budapest (www.gastro-up-
date-europe.eu)
Figure 10. Kandiah et al., Gut 2017 Sep 28. pii: gutjnl-2017-314512
 Morphological Features Classification Barrett’s diagnosis
Acetow-
hitening 
No focal loss of acetowhitening Absent Non-neoplastic 
Focal loss of acetowhitening Present Neoplastic 
Surface 
Pattern 
Uniform evenly spaced pits with nor-
mal pit density 
Normal Non-neoplastic 
Compactly packed small pits with 
increased pit density
Abnormal Neoplastic 
Focal irregularity or disorganized pits 
Absent pit pattern
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Another intriguing finding from the pro-
spective Nurses’ Health Study (1984–2012), 
and from the Health Professionals Follow-up 
study (1986–2012 — median follow-up 
7.8 y) is a reduced all-cause and especially 
colorectal cancer-specific death after con-
suming 4 or more cups of coffee, including 
decaffeinated, per day as shown in Figure 11. 
Again, further studies are needed to de-
termine the potential mechanisms by which 
coffee may reduce colorectal cancer progres-
sion with ongoing attention for confounders.
Specific bacterial strains may play a role 
in colorectal carcinogenesis. In an intrigu-
ing study, over 13,000 patients with blood 
culture positive bacteremia were compared 
with over 32,000 well matched blood culture 
The incidence of colorectal cancer in 
individuals < 50 years old is on the rise, re-
lated perhaps to the obesity epidemic and in-
creased frequency of germline genetic chang-
es. A large retrospective analysis was carried 
out in 430 young colorectal cancer patients. 
20% carried germline mutations associated 
with cancer predisposition (mostly mutations 
in Lynch MMR, but also APC gene and other 
variants). Importantly, half of the individuals 
with genetic diagnosis did not have a typical 
family history. Testing with multigene panels 
for germline sequencing of such individuals 
is strongly recommended.
Changes in the microbiota after use of 
antibiotics may play a role in colorectal can-
cer pathogenesis. Further support for this 
concept was recently provided by the long-
term follow of the Nurses’ Health Study. An-
tibiotic use for > 2 months during age 20–39 
y increased the risk for colorectal adenoma 
to an OR 1.36, and antimicrobial exposure 
during age 40–59 to an OR 1.69. Obvious-
ly, further studies are required to clarify the 
role of the altered microbial composition af-
ter antibiotic use and its duration with respect 
to the mechanisms of carcinogenesis. Elimi-
nation of confounders will be of crucial im-
portance, but in all probability the (altered?) 
microbiome is involved in colorectal cancer 
pathogenesis.
Figure 11. Association between coffee intake after diagno-
sis of colorectal cancer mortality [Hu et al., Gastroentero-
logy 2018; 154: 916]
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negative controls. Among the bacteria re-
sponsible for bacteremia and sepsis were 
Bacteroides, Streptococcus, Fusobacterium, 
Peptostreptococcus, and Clostridium. Many 
of the bacteremia-positive patients were as-
sociated with a later diagnosis of colorectal 
cancer. The take-home message of that stu-
dy was that clinicians should evaluate pa-
tients with bacteremia with specific species 
for neoplasia in the large bowel. Apparently 
cancerous growth in the colon, with disrup-
ted barriers, allows bacterial penetration and 
ultimately bacteremia.
After therapy for colorectal cancer, rou-
tine follow-up is usually performed in clini-
cal practice. To find out if there is an outcome 
difference between intensive or less intensi-
ve follow-up, over 2,509 patients with initial 
stage II/III colorectal cancer were analysed 
after intended curative surgery. Intensive fol-
low-up consisted of multi-sliced, contrast-en-
hanced CT of abdomen and chest, plus CEA 
at 6, 12, 18, 24, and 36 months. Less intensi-
ve follow-up consisted of the same regimen 
but only at 12 and 36 months. The 5 y ove-
rall, and colorectal cancer-specific mortality, 
were indistinguishable (Fig. 12).
Such outcome is similar to what has 
been seen for post-therapy gastric cancer 
follow-up. Such intensive follow-up is very 
costly, often redundant and medically non-
-contributory, and should probably be di-
scouraged. However, close monitoring post 
cancer therapy is so entrenched in clinical 
practice that a rapid change in attitude is 
not to be expected. An individualized appro-
ach would seem preferable, based upon the 
specific medical situation, but also the psy-
chological make-up of the individual requi-
ring and benefitting from close physician-
-patient interaction.
Effectiveness of colorectal cancer 
screening depends on key factors, summari-
zed below (Fig. 13). 
Previous studies have shown that the 
higher the adenoma detection rate, the lo-
wer the risk of interval colorectal cancer. 
Improvement of the adenoma detection rate 
through training has now been shown to 
lead to a decreased risk of interval cancer 
and to decreased cancer death. Colonosco-
pic improvement is necessary because the 
interval cancer rate overall stays at around 
8%! High detectors remove more neopla-
stic lesions and they instruct more patients 
to return at shorter intervals for surveillan-
ce endoscopy; both factors contributing to 
superior results and lower interval cancers. 
Compliance
Population adheres 
to colonoscopy
Efficacy
High detection rates for 
adenomas and cancer
Quality
High endoscopist 
performance, low 
complication rate
Treatment
Early stage treatment 
more beneficial than 
late stage treatment
Colonoscopy screening 
effectiveness
Reduction of colorectal 
cancer incidence 
and mortality
Figure 13. Robertson, Kaminski, Bretthauer, Gut 2015; 
64: 982
Figure 12. Wille-Jorgensen et al., JAMA 2018; 319: 2095
Cancer-specific mortality by time from colorectal cancer 
surgery in intention-to-treat analysis
Mortality by time from colorectal cancer surgery in 
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Colonoscopy should not be delayed after 
a positive FIT test. In a large American stu-
dy involving over 70,000 patients with a po-
sitive FIT test, 2,191 cancers were detected 
at colonoscopy. Comparing early colono-
scopy (within 30 days) with late colonosco-
py (delay over 10 months), after a positive 
FIT revealed that delayed colonoscopy had 
a higher risk of colorectal cancer and more 
advanced disease stages.
A significant complication of diverti-
cular disease is bleeding. Fortunately, spon-
taneous cessation occurs in ~75%. Colono-
scopic attempt at hemostasis is usually the 
first investigation if bleeding continues. In 
a systematic review and meta-analysis, invol-
ving 384 patients, coagulation was compared 
to clipping and to band ligation. The endpo-
ints were: initial hemostasis, 30-day bleeding 
recurrence, and need for embolisation of the 
feeding artery. Initial hemostasis and early 
bleeding recurrence occurred at roughly si-
milar rates for banding, coagulation and clip-
ping. Band ligation, however, was most ef-
ficient in terms of avoiding surgery and em-
bolization, and should probably become the 
therapy of choice.
The 6th Gastro Update Europe is June 14 
– 15, 2019 in Budapest (www.gastro-update-
-europe.eu)
